AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8669413 — intervention group
Group type: COMPARATOR
Intervention: Fiber-supplemented diet followed by labeled oat bran test meal
Number of subjects: 6
Study 1812478 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 21
Study 6872291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 28
Study 6872291 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 28
Study 6872291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and its metabolites
Number of subjects: 28
Study 6872291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid
Number of subjects: 28
Study 31566149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution rate 1:4
Number of subjects: 4
Study 31566149 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibration time 1 h
Number of subjects: 4
Study 28506956 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (internet-based cognitive behavioral therapy)
Number of subjects: 91
Study 28506956 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 91
Study 27746112 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum intravenous busulfan AUC of 78–101 mg×h/L
Number of subjects: 674
Study 27746112 — intervention group
Group type: COMPARATOR
Intervention: Low historical target of 58–86 mg×h/L
Number of subjects: 674
Study 27746112 — intervention group
Group type: COMPARATOR
Intervention: High busulfan AUC (>101 mg×h/L)
Number of subjects: 674
Study 27746112 — intervention group
Group type: COMPARATOR
Intervention: Low AUC (<78 mg×h/L)
Number of subjects: 674
Study 24670970 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose freeze-dried strawberries (HD-FDS; 50 g/d)
Number of subjects: 60
Study 24670970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose freeze-dried strawberries (LD-FDS; 25 g/d)
Number of subjects: 60
Study 24670970 — intervention group
Group type: COMPARATOR
Intervention: High-dose control (HD-C)
Number of subjects: 60
Study 24670970 — intervention group
Group type: COMPARATOR
Intervention: Low-dose control (LD-C)
Number of subjects: 60
Study 22853453 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusch intubation stylet (Group S)
Number of subjects: 103
Study 22853453 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 103
Study 20477765 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for unhealthy alcohol use
Number of subjects: 341
Study 20477765 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-attributable principal admitting diagnosis
Number of subjects: 341
Study 20477765 — intervention group
Group type: COMPARATOR
Intervention: Alcohol dependence or high problem perception
Number of subjects: 341
Study 17622238 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 26
Study 17622238 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 26
Study 15826438 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 32
Study 12166542 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg once daily)
Number of subjects: 111
Study 12166542 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine (up to 6 mg twice daily)
Number of subjects: 111
Study 10223557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg twice daily)
Number of subjects: 125
Study 10223557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 7784338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma scintigraphy
Number of subjects: 8
Study 7784338 — intervention group
Group type: COMPARATOR
Intervention: Pharmacokinetic (charcoal-block) method
Number of subjects: 8
Study 7784338 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI with slow inhalation (27 l/min)
Number of subjects: 8
Study 7784338 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI with fast inhalation (151 l/min)
Number of subjects: 8
Study 7784338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler large volume spacer device (average inhaled flow 17 l/min)
Number of subjects: 8
Study 1519031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 58
Study 1519031 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58
Study 1519031 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 3 mg/kg
Number of subjects: 58
Study 1519031 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg
Number of subjects: 58
Study 6375756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride 24 mg per day
Number of subjects: 40
Study 6375756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 90 mg per day
Number of subjects: 40
Study 6375756 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Chymotrypsin buccle 100 ch.u. per day
Number of subjects: 40
Study 6375756 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratiopeptidase 30 mg per day
Number of subjects: 40
Study 6375756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31483785 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic diet for 40 days
Number of subjects: 149
Study 31483785 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet for 40 days
Number of subjects: 149
Study 29573657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study 25584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic neuropathy
Number of subjects: 635
Study 25584994 — intervention group
Group type: COMPARATOR
Intervention: Erectile dysfunction and lower urinary tract symptoms
Number of subjects: 635
Study 23630210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× HD‐AraC (high-dose cytarabine consolidation with three cycles of 18 g/m(2))
Number of subjects: 1179
Study 23630210 — intervention group
Group type: COMPARATOR
Intervention: MAC/MAMAC/MAC (multiagent consolidation with two cycles of mitoxantrone 30 mg/m(2) plus cytarabine 12 g/m(2) and one cycle of amsacrine 500 mg/m(2) plus cytarabine 10 g/m(2))
Number of subjects: 1179
Study 23630210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× HD‐AraC
Number of subjects: 1179
Study 23630210 — intervention group
Group type: COMPARATOR
Intervention: MAC/MAMAC/MAC
Number of subjects: 1179
Study 21336959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal orthotopic neobladder (ONB)
Number of subjects: 39
Study 21336959 — intervention group
Group type: COMPARATOR
Intervention: Uretero-ureterocutaneostomy (UUC)
Number of subjects: 39
Study 19226239 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training
Number of subjects: 48
Study 19226239 — intervention group
Group type: COMPARATOR
Intervention: Home-based balance training
Number of subjects: 48
Study 17099670 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial trauma‐based brief intervention (visual presentation with information and photographs)
Number of subjects: 242
Study 17099670 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 242
Study 15306031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobics in bright light
Number of subjects: 98
Study 15306031 — intervention group
Group type: COMPARATOR
Intervention: Aerobics in normal room lighting
Number of subjects: 98
Study 15306031 — intervention group
Group type: COMPARATOR
Intervention: Relaxation/stretching in bright light
Number of subjects: 98
Study 11301186 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor mobilization
Number of subjects: 50
Study 8770427 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of more than 25 tablets
Number of subjects: 80
Study 8770427 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose preparation of tablets
Number of subjects: 80
Study 8770427 — intervention group
Group type: COMPARATOR
Intervention: Blister-pack preparation of tablets
Number of subjects: 80
Study 8770427 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning labels
Number of subjects: 80
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy (10 x 2 Gy) to the hemithorax + CYVADIC (cyclophosphamide 500 mg/m2 d 1, vincristine 1 mg/m2 d 1 and 5, adriamycin 40 mg/m2 d 1 and dacarbazine 200 mg/m2 d 1 and 5, several cycles before and after irradiation)
Number of subjects: 100
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 Gy (25 x 2.2 Gy) to the hemithorax + 15 Gy (6 x 2.5 Gy) to the tumor + CYVADIC (2 cycles before, 1 cycle during, and 2 cycles after irradiation)
Number of subjects: 100
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2 q 28 d, < or = 6 cycles) followed by 70 Gy (56 x 1.25 Gy, twice a day)
Number of subjects: 100
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Epirubicin (110‐130 mg/m2 q 28 d, < or = 6 cycles) followed by 35 Gy (28 x 1.25 Gy twice a day) to the hemithorax + 36 Gy (9 x 4 Gy every 2 days) to the tumor
Number of subjects: 100
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (150 mg/m2 1, 3, 5 q 28 d) followed by 38.5 Gy (11 x 3.5 Gy) to the hemithorax
Number of subjects: 100
Study 1429086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment programs
Number of subjects: 100
Study 3882141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (12.5 mg/kg/d orally or 3 mg/kg/d i.v.)
Number of subjects: 112
Study 3882141 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 112
Study 31204776 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based occupational therapy with sensor monitoring
Number of subjects: 240
Study 31204776 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 240
Study 30325357 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic noise exposure
Number of subjects: 250
Study 30325357 — intervention group
Group type: COMPARATOR
Intervention: Protective equipment to control noise
Number of subjects: 250
Study 25932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (GAL) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9
Study 25932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (GLU) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9
Study 25932956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) drink (artificially sweetened, 45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Number of subjects: 9
Study 25932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (GAL) drink (45 g of CHO)
Number of subjects: 9
Study 25284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity group (n=30)
Number of subjects: 90
Study 25284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise group (n=30)
Number of subjects: 90
Study 25284708 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n=30)
Number of subjects: 90
Study 22500388 — intervention group
Group type: EXPERIMENTAL
Intervention: QYBCR (qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe)
Number of subjects: 78
Study 22500388 — intervention group
Group type: EXPERIMENTAL
Intervention: QYBCR
Number of subjects: 78
Study 22500388 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 78
Study 19804966 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening in Rotterdam (intervention group)
Number of subjects: 149257
Study 19804966 — intervention group
Group type: COMPARATOR
Intervention: No PSA screening in Northern Ireland (control group)
Number of subjects: 149257
Study 17643057 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 x 600 mg orally for 6 weeks
Number of subjects: 30
Study 17643057 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 30
Study 16226162 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 4162
Study 16226162 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 4162
Study 12394531 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (7.2 g daily for the first 2 weeks during ECT, followed by 4.8 g thereafter)
Number of subjects: 38
Study 12394531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking)
Number of subjects: 38
Study 10687162 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite (3 g/day for children under 3 years and 6 g/day for children over 3 years)
Number of subjects: 35
Study 10687162 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) only
Number of subjects: 35
Study 10687162 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite and ORS
Number of subjects: 35
Study 8656345 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical and model‐based methods for estimating AUC and Cmax
Number of subjects: 0
Study 8656345 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐based sampling times obtained by software
Number of subjects: 0
Study 2205129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours with 2 mL/kg of water
Number of subjects: 100
Study 2205129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 4 hours
Number of subjects: 100
Study 2205129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 6 hours
Number of subjects: 100
Study 720003 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (single dose)
Number of subjects: 0
Study 30223083 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/day
Number of subjects: 24
Study 30223083 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 28838475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 62
Study 25377657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-emission UV treatment and mometasone ointment 0.1%
Number of subjects: 62
Study 25377657 — intervention group
Group type: COMPARATOR
Intervention: Mometasone ointment 0.1% alone
Number of subjects: 62
Study 22704916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 777
Study 22704916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 777
Study 21317700 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and documentation practices of emergency department nurses for MTBI
Number of subjects: 0
Study 21317700 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignment with CDC guidelines for MTBI assessment
Number of subjects: 0
Study 19594043 — intervention group
Group type: EXPERIMENTAL
Intervention: EKRL training
Number of subjects: 150
Study 19594043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (EKRL training + Meloxicam)
Number of subjects: 150
Study 19594043 — intervention group
Group type: COMPARATOR
Intervention: Control group (Meloxicam only)
Number of subjects: 150
Study 17266171 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐h tobacco‐deprived smokers
Number of subjects: 90
Study 17266171 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 90
Study 17266171 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived smokers
Number of subjects: 90
Study 15016023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation (curettes, hoes and files)
Number of subjects: 20
Study 15016023 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating power-driven instruments
Number of subjects: 20
Study 15016023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler alone
Number of subjects: 20
Study 15016023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of ultrasonic scaler and power-driven inserts
Number of subjects: 20
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass‐ionomer cement (Ketac‐Molar aplicap)
Number of subjects: 60
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (Heliomolar)
Number of subjects: 60
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass‐ionomer (Fuji II LC)
Number of subjects: 60
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Compoglass)
Number of subjects: 60
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Hytac)
Number of subjects: 60
Study 12049082 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorative material (Dyract)
Number of subjects: 60
Study 9786104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 48
Study 9786104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 48
Study 9786104 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 48
Study 9786104 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 48
Study 7838889 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg BMS-181168
Number of subjects: 16
Study 7838889 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BMS-181168
Number of subjects: 16
Study 7838889 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg BMS-181168
Number of subjects: 16
Study 7838889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3283620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive maintenance treatment (rotating combination of HD‐Ara C, mAMSA, 5‐AZA)
Number of subjects: 63
Study 3283620 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated induction type chemotherapy (DNM, VCR, Ara C)
Number of subjects: 63
Study 3283620 — intervention group
Group type: COMPARATOR
Intervention: Conventional maintenance treatment (from a preceding randomized study)
Number of subjects: 63
Study 29413364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5g/day Arachidonic acid (ARA) for 4 weeks
Number of subjects: 19
Study 29413364 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study 28662808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 359
Study 28662808 — intervention group
Group type: COMPARATOR
Intervention: Metallic drug-eluting stent (DES)
Number of subjects: 359
Study 25650633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular blockade with 30 mL of 0.5% ropivacaine
Number of subjects: 64
Study 25650633 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided infraclavicular blockade with 30 mL of 0.5% ropivacaine
Number of subjects: 64
Study 23974885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs) for 3 months, replaced every 30 days
Number of subjects: 29
Study 23974885 — intervention group
Group type: COMPARATOR
Intervention: Ocular lubricants (OLs) 4 times a day with Lacri-Lube ointment at night for 3 months
Number of subjects: 29
Study 19788708 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietetic advice for CHD
Number of subjects: 61
Study 19788708 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural counselling for Mediterranean diet
Number of subjects: 61
Study 19788708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling for Mediterranean diet
Number of subjects: 61
Study 18775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive manual thrombectomy
Number of subjects: 2417
Study 18775918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2417
Study 16416358 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 56
Study 16416358 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 56
Study 16416358 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline-gabapentin combination
Number of subjects: 56
Study 12888055 — intervention group
Group type: EXPERIMENTAL
Intervention: Eger Macular Stressometer (EMS) for AMD group
Number of subjects: 92
Study 12888055 — intervention group
Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for normal/mild cataract group
Number of subjects: 92
Study 12888055 — intervention group
Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for diabetic retinopathy group
Number of subjects: 92
Study 12888055 — intervention group
Group type: COMPARATOR
Intervention: Eger Macular Stressometer (EMS) for glaucoma group
Number of subjects: 92
Study 10700783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.5 mg kg‐1
Number of subjects: 42
Study 10700783 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg kg‐1
Number of subjects: 42
Study 10700783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42
Study 10700783 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9488 (main metabolite)
Number of subjects: 42
Study 10700783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 42
Study 10700783 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 42
Study 8947715 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly electronic mail message with computer-generated report summarizing adherence to care guidelines for diabetic patients.
Number of subjects: 45
Study 8947715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individualized feedback).
Number of subjects: 45
Study 2016605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty (Charnley)
Number of subjects: 150
Study 2016605 — intervention group
Group type: COMPARATOR
Intervention: Noncemented total hip arthroplasty (HP‐Garches)
Number of subjects: 150
Study 6105476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative B-mode ultrasound scanning
Number of subjects: 50
Study 6105476 — intervention group
Group type: COMPARATOR
Intervention: Per-operative cholangiography
Number of subjects: 50
Study 31905382 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar adalimumab (SB5)
Number of subjects: 93
Study 31905382 — intervention group
Group type: COMPARATOR
Intervention: Originator adalimumab
Number of subjects: 93
Study 31481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tuberoplasty
Number of subjects: 140